Median Technologies to Present eyonis™ LCS AI Software for Lung Cancer Screening at ECR
Median Technologies, a leader in artificial intelligence (AI)-powered software for early cancer diagnostics, has announced its participation in the 2025 European Congress of Radiology (ECR) in Vienna from February 26 to March 2. The company, known for its pioneering eyonis™ suite, will showcase its cutting-edge Software as a Medical Device (SaMD) for lung cancer screening, eyonis™ LCS, at the event. The eyonis™ team will be present at Booth #AI-18 in the AI Exhibition, Expo X1, during the technical exhibits from February 26 to March 1.
The company will present the latest developments in eyonis™ LCS, its AI-powered solution designed to improve the accuracy and efficiency of lung cancer diagnosis, particularly in screening with low-dose computed tomography (LDCT). Recent results from the pivotal RELIVE study, the second of two critical trials required for marketing authorization in the U.S. and Europe, showed that eyonis™ LCS met its primary endpoint with statistical significance. The results from the secondary endpoints will be shared once all statistical analyses are complete.
The pivotal trials, RELIVE and REALITY, were designed based on discussions with the FDA to evaluate eyonis™ LCS. Both studies aimed to demonstrate clinical validation for the AI software, with the RELIVE trial confirming its efficacy in improving the diagnostic process. With these successes, Median Technologies is preparing to submit regulatory dossiers for the U.S. 510(k) clearance and European CE marking for eyonis™ LCS in the second quarter of 2025.
Thomas Bonnefont, COO and CCO of the eyonis™ Business Unit at Median Technologies, emphasized the significance of the study’s results. “These pivotal study results suggest that eyonis™ LCS can enable the widespread implementation of LDCT lung cancer screening procedures by improving the accuracy of lung cancer diagnoses,” Bonnefont said. “Our goal is to provide a more efficient and accurate diagnostic tool that can address the complexities of analyzing LDCT images and streamline the screening process.”
As part of the ECR event, Median Technologies will host an industry presentation titled “eyonis™ LCS: Pioneering AI/ML Software as a Medical Device Redefining the Future of Lung Cancer Screening,” presented by Valérie Bourdès, MD, VP of Clinical and Medical Affairs. This presentation will take place in the AI Lightning Talks 3 session on Wednesday, February 26, from 13:30 to 14:30 CET at the AI Theatre, ACV Building Level -2. This session will explore how eyonis™ LCS is set to transform the landscape of lung cancer diagnostics and its potential to significantly enhance patient outcomes.
Additionally, Median Technologies will present a research paper titled “Discord Dilemmas in Lung Cancer Clinical Trials: Navigating Reader Variability in Response Assessment” at the Oncologic Imaging session. The research presentation will be delivered by Hubert Beaumont, Lead Scientist at Median Technologies, on Wednesday, February 26, from 8:00 to 9:30 CET at the ACV Building, Research Stage 3. The study will delve into the challenges of reader variability in clinical trials and the role of advanced imaging technology in resolving these issues.
eyonis™ LCS is designed to assist healthcare professionals in diagnosing lung cancer at its earliest stages by analyzing LDCT imaging data using machine learning techniques. Early detection is crucial in improving patient prognosis, as lung cancer is often most treatable when caught in its initial stages. The two pivotal studies, REALITY and RELIVE, are essential for obtaining the necessary marketing approvals for eyonis™ LCS in both the U.S. and Europe. Median Technologies expects to submit the regulatory filings based on these pivotal study results in Q2 2025.
Median Technologies is committed to advancing the field of cancer diagnostics with innovative imaging solutions. The company’s portfolio includes not only the eyonis™ suite of SaMD but also iCRO, a service that provides medical image analysis and management for oncology trials. By harnessing AI and machine learning, Median Technologies is leading the way in early cancer detection and improving the efficiency of clinical trials. The company aims to expedite the development of new cancer therapies by offering powerful diagnostic tools that support biopharmaceutical companies and clinicians in advancing patient care.
Founded in France with a presence in the U.S. and China, Median Technologies is a publicly traded company on the Euronext Growth market. Its stock is eligible for the French SME equity savings plan scheme (PEA-PME), and it continues to drive innovation in the field of AI-powered medical imaging. With the ongoing development of eyonis™ LCS and its other advanced imaging solutions, Median Technologies is poised to make a significant impact in the oncology space.
